Serum matrix metalloproteinase‐9 and venous bypass graft occlusion

References

• Fitzgibbon G. M., Kafka H. P., Leach A. J., Keon W. J., Hooper G. D., Burton J. R. Coronary bypass graft fate and patient outcome: angiographic follow‐up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616–26
   PubMed Web of Science ®Google Scholar
• Korpilahti K., Engblom E., Hämäläinen H., Syvänne M., Hietanen E., Arstila M., et al. Significance of graft occlusion and coronary atherosclerosis 5 years after coronary artery bypass grafting. A quantitative angiographic study with serial exercise testing. J Intern Med 1999; 245: 545–52
   PubMed Web of Science ®Google Scholar
• Mills N. L., Everson C. T. Vein graft failure. Curr Opin Cardiol 1995; 10: 562–8
   PubMed Web of Science ®Google Scholar
• Cox J. L., Chiasson D. A., Gotlieb A. I. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45–68
   PubMed Web of Science ®Google Scholar
• Morton K. E., Gavaghan T. P., Krilis S. A., Daggard G. E., Baron D. W., Hickie J. B., et al. Coronary artery bypass graft failure: an autoimmune phenomenon?. Lancet 1986; 2: 1353–7
   PubMed Web of Science ®Google Scholar
• Limnell V., Aittoniemi J., Vaarala O., Lehtimäki T., Laine S., Virtanen V., et al. Association of mannan‐binding lectin deficiency with venous bypass graft occlusion in patients with coronary heart disease. Cardiology 2002; 98: 123–6
   PubMed Web of Science ®Google Scholar
• Galis Z., Sukhova G., Lark M., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493–503
   PubMed Web of Science ®Google Scholar
• Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteinases ‐2 and ‐9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368–72
   PubMed Web of Science ®Google Scholar
• Noji Y., Kajinami K., Kawashiri M., Todo Y., Horita T., Nohara A., et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: 380–4
   PubMed Web of Science ®Google Scholar
• Meng X., Mavromatis K., Galis Z. S. Mechanical stretching of human saphenous vein grafts induces expression and activation of matrix‐degrading enzymes associated with vascular tissue injury and repair. Exp Mol Pathol 1999; 66: 227–37
   PubMed Web of Science ®Google Scholar
• Porter K. E., Thompson M. M., Loftus I. M., McDermott E., Jones L., Crowther M., et al. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur J Vasc Endovasc Surg 1999; 17: 404–12
   PubMed Web of Science ®Google Scholar
• Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol: modification of low density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320: 915–24
   PubMed Web of Science ®Google Scholar
• Palinski W., Rosenfeld M. E., Ylä‐Herttuala S., Gurtner G. C., Socher S. S., Butler S. W., et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372–6
   PubMed Web of Science ®Google Scholar
• Ylä‐Herttuala S., Palinski W., Butler S. W., Picard S., Steinberg D., Witztum J. L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32–40
   PubMed Web of Science ®Google Scholar
• Lehtimäki T., Lehtinen S., Solakivi T., Nikkilä M., Jaakkola O., Jokela H., et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23–7
   PubMed Web of Science ®Google Scholar
• Eber B., Schumacher M., Tatzber F., Kaufmann P., Luha O., Esterbauer H., et al. Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty. Cardiology 1994; 84: 310–5
   PubMed Web of Science ®Google Scholar
• Xu X. P., Meisel S. R., Ong J. M., Kaul S., Cercek B., Rajavashisth T. B., et al. Oxidized low‐density lipoprotein regulates matrix metalloproteinase‐9 and its tissue inhibitor in human monocyte‐derived macrophages. Circulation 1999; 99: 993–8
   PubMed Web of Science ®Google Scholar
• Kalela A., Koivu T. A., Höyhtyä M., Jaakkola O., Lehtimäki T., Sillanaukee P., et al. Association of serum MMP‐9 with autoantibodies against oxidized LDL. Atherosclerosis 2002; 160: 161–5
   PubMed Web of Science ®Google Scholar
• Knatterud G. L., White C., Geller N. L., Campeau L., Forman S. A., Domanski M., et al. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J 2003; 145: 262–9
   PubMed Web of Science ®Google Scholar
• Renko J., Kalela A., Jaakkola O., Laine S., Höyhtyä M., Alho H., et al. Serum matrix metalloproteinase‐9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest 2004; 64: 255–61
   PubMed Web of Science ®Google Scholar
• Erkkilä A. T., Narvanen O., Lehto S., Uusitupa M. I., Ylä‐Herttuala S. Autoantibodies against oxidized low‐density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 204–9
   PubMed Web of Science ®Google Scholar
• Soini Y., Hurskainen T., Höyhtyä M., Oikarinen A., Autio‐Harmainen H. 72 kD and 92 kD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 1994; 42: 945–51
   PubMed Web of Science ®Google Scholar
• Kalela A., Koivu T. A., Sisto T., Kanervisto J., Höyhtyä M., Sillanaukee P., et al. Serum matrix metalloproteinase‐9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62: 337–42
   PubMed Web of Science ®Google Scholar
• Lindsey M., Wedin K., Brown M. D., Keller C., Evans A. J., Smolen J., et al. Matrix‐dependent mechanism of neutrophil‐mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103: 2181–7
   PubMed Web of Science ®Google Scholar
• Tziakas D. N., Chalikias G. K., Parissis J. T., Hatzinikolaou E. I., Papadopoulos E. D., Tripsiannis G. A., et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short‐term atorvastatin administration. Int J Cardiol 2004; 94: 269–77
   PubMed Web of Science ®Google Scholar
• Porter K. E., Loftus I. M., Peterson M., Bell P. R., London N. J., Thompson M. M. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Br J Surg 1998; 85: 1373–7
   PubMed Web of Science ®Google Scholar
• George S. J., Zaltsman A. B., Newby A. C. Surgical preparative injury and neointima formation increase MMP‐9 expression and MMP‐2 activation in human saphenous vein. Cardiovasc Res 1997; 33: 447–59
   PubMed Web of Science ®Google Scholar
• Porter K. E., Naik J., Turner N. A., Dickinson T., Thompson M. M., London N. J. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36: 150–7
   PubMed Web of Science ®Google Scholar
• George J., Harats D., Bakshi E., Adler Y., Levy Y., Gilburd B., et al. Anti‐oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 1999; 68: 263–6
   PubMed Web of Science ®Google Scholar